The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationTuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Cancer risk in patients with inflammatory bowel disease: A population-based study
Bernstein, C. N., Blanchard, J. F., Kliewer, E., & Wajda, A. (2001) · Cancer · doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z · Cited by 1,165
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Bégaud, B., Evreux, J. C., Jouglard, J., & Lagier, G. (1985) · PubMed · Cited by 966
Brown, S. L., Greene, M. H., Gershon, S. K., Edwards, E. T., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10679 · Cited by 655
Crohn's disease in Olmsted County, Minnesota, 1940–1993: Incidence, prevalence, and survival
Loftus, E. V., Silverstein, M. D., Sandborn, W. J., Tremaine, W. J., Harmsen, W. S., & Zinsmeister, A. R. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70421-4 · Cited by 623
Self-citationWeedon, D. D., Shorter, R. G., Ilstrup, D. M., Huizenga, K. A., & Taylor, W. F. (1973) · New England Journal of Medicine · doi:10.1056/nejm197311222892101 · Cited by 467
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
Kwon, H. J., Cot, T. R., Cuffe, M. S., Kramer, J. M., & Braun, M. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-10-200305200-00008 · Cited by 455
Induction of Nod2 in Myelomonocytic and Intestinal Epithelial Cells via Nuclear Factor-κB Activation
Gutierrez, O., Pipaon, C., Inohara, N., Fontalba, A., Ogura, Y., Prosper, F., Nuñez, G., & Fernandez-Luna, J. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206473200 · Cited by 444
Lee, J., Slifman, N. R., Gershon, S. K., Edwards, E. T., Schwieterman, W. D., Siegel, J. N., Wise, R. P., Brown, S. L., Udall, J. N., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10583 · Cited by 443
Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy
(2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441415 · Cited by 330
Vermeire, S., Noman, M., Van Assche, G., Baert, F., Van Steen, K., Esters, N., Joossens, S., Bossuyt, X., & Rutgeerts, P. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00701-7 · Cited by 327
Crohn's disease and cancer: A population-based cohort study
Persson, P.-G., Karlén, P., Bernell, O., Leijonmarck, C.-E., Broström, O., Ahlbom, A., & Hellers, G. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90807-9 · Cited by 306
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
Ricart, E., Panaccione, R., Loftus, E. V., Tremaine, W. J., & Sandborn, W. J. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03612.x · Cited by 285
Self-citationInfliximab in Crohn's Disease: First Anniversary Clinical Experience
Cohen, R. D., Tsang, J. F., & Hanauer, S. B. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03363.x · Cited by 229
Vermeire, S. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04348-4 · Cited by 229
Extracolonic malignancies in inflammatory bowel disease
Ekbom, A., Helmick, C., Zack, M., & Adami, H.-O. (1991) · Cancer · doi:10.1002/1097-0142(19910401)67:7<2015::aid-cncr2820670731>3.0.co;2-r · Cited by 226
Clinical experience with infliximab therapy in 100 patients with Crohn's disease
Farrell, R. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02159-6 · Cited by 209
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians
Sandborn, W. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05510-7 · Cited by 203
Self-citationJess, T., Winther, K. V., Munkholm, P., Langholz, E., & Binder, V. (2002) · Gastroenterology · doi:10.1053/gast.2002.33632 · Cited by 191
Survival and cause-specific mortality in inflammatory bowel disease: A population-based cohort study
Persson, P., Bernell, O., Leijonmarck, C., Farahmand, B., Hellers, G., & Ahlbom, A. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613037 · Cited by 174
Palli, D., Trallori, G., Saieva, C., Tarantino, O., Edili, E., D'Albasio, G., Pacini, F., & Masala, G. (1998) · Gut · doi:10.1136/gut.42.2.175 · Cited by 136
Kugathasan, S., Levy, M. B., Saeian, K., Vasilopoulos, S., Kim, J. P., Prajapati, D. N., Emmons, J. E., Martínez, A., Kelly, K. J., & Binion, D. G. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05784.x · Cited by 123
Demyelination During Anti-Tumor Necrosis Factor α Therapy With Infliximab for Crohn's Disease
Thomas, C. W., Weinshenker, B. G., & Sandborn, W. J. (2003) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200401000-00004 · Cited by 118
Self-citationReactivation of histoplasmosis after treatment with infliximab
Nakelchik, M., & Mangino, J. E. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00945-7 · Cited by 108
Long Term Safety of Infliximab
Schaible, T. F. (2000) · Canadian Journal of Gastroenterology · doi:10.1155/2000/698523 · Cited by 103
Puchner, T. C., Kugathasan, S., Kelly, K. J., & Binion, D. G. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200102000-00005 · Cited by 91
Listeria Meningitis After Treatment With Infliximab
Kamath, B. M., Mamula, P., Baldassano, R. N., et al. (2002) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200204000-00018 · Cited by 86
Riegert‐Johnson, D. L., Godfrey, J. A., Myers, J. L., Hubmayr, R. D., Sandborn, W. J., & Loftus, E. V. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200205000-00005 · Cited by 79
Self-citationDoes administration of Infliximab increase susceptibility to listeriosis?
Morelli, J., & Wilson, F. A. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01872.x · Cited by 72
Infliximab Treatment for Crohn's Disease: One-Year Experience in a Dutch Academic Hospital
Hommes, D. W., van de Heisteeg, B., van der Spek, M., Bartelsman, J. F. W. M., & van Deventer, S. J. H. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200203000-00002 · Cited by 62
Maintenance infliximab for Crohn's disease
Hanauer, S. B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11537-6 · Cited by 44
Infliximab treatment for Crohn's disease
Conroy, C., & Cattell, R. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.909.436 · Cited by 26
Sáez, L. R. (2004) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082004000600001 · Cited by 14
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Cited by
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationKornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Microbial Influences in Inflammatory Bowel Diseases
Sartor, R. B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.059 · Cited by 1,927
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Self-citationGuidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Metadata
- Authors
- Colombel, J.-F., Loftus, E. V., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R., & Sandborn, W. J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2004-01
- Volume
- 126
- Issue
- 1
- Pages
- 19-31
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2127693350
- Cited by
- 899
- References
- 40
- FWCI
- 36.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.